logo
  Join        Login             Stock Quote

Mylan (MYL) Launches Generic Version Of Merck's (MRK) Migraine Drug

 January 02, 2013 01:27 PM
 


(By Balaseshan) Mylan Inc. (NASDAQ: MYL) said its subsidiary launched the generic version of Merck & Co. Inc.'s (NYSE: MRK) Maxalt MLT and Maxalt tablets to treat acute migraine with or without aura in adults.

Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Applications (ANDA) for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base).

[Related -Forest Laboratories, Inc. (NYSE:FRX): Should Astrazeneca Plc Buy Forest Labs?]

Mylan is shipping the orally disintegrating and immediate-release versions of this product immediately.

These products are the generic versions of Merck's Maxalt MLT Tablets and Maxalt Tablets, respectively, and are indicated for the acute treatment of migraine with or without aura in adults.

Mylan was the first company to have filed a substantially complete ANDA containing a Paragraph IV certification for Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), and was awarded 180 days of marketing exclusivity.

Rizatriptan Benzoate Orally Disintegrating Tablets, 5 mg (base) and 10 mg (base), had U.S. sales of about $262.5 million for the twelve months ending September 30, 2012, according to IMS Health, and Rizatriptan Benzoate Tablets, 5 mg (base) and 10 mg (base), had U.S. sales of about $344.7 million for the same period.

[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]

On December 28, 2012, the company's partner Famy Care Ltd. has launched Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva (NYSE: TEVA) Branded Pharmaceutical Products' Nordette 28 Tablets.

The product will be distributed in the U.S. by Mylan Pharmaceuticals Inc., and the company is shipping product immediately. Nordette 28 Tablets are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception.

Mylan Pharmaceuticals also launched Phenytoin Chewable Tablets USP, 50 mg, which is the generic version of Pfizer's (NYSE: PFE) Dilantin Chewable Tablets. Mylan is shipping this product immediately.

Dilantin Tablets are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments

MYL is trading up 0.07% at $27.47 on Wednesday. The stock has been trading between $20.21 and $28.50 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageThe Boeing Company (BA) Q2 Earnings Preview: Durable Earnings Beater

The Boeing Company (NYSE:BA) will publish its second-quarter financial results before the open of the read on...

article imageAngie's List Inc. (ANGI) Q2 Earnings Preview: Trending Towards a Smaller Loss than Expected

Angie's List Inc. (NASDAQ:ANGI) will post its second quarter 2014 financial results will be released on read on...

article imageMicrosoft Corporation (MSFT) Q4 Earnings Preview: Xbox and Surface Margins the Key

Microsoft Corporation (NASDAQ:MSFT) will publish fiscal year 2014 fourth-quarter financial results after read on...

article imageBaidu Inc. (BIDU): Climbing Towards Morgan Stanley’s $239.30 Target

Baidu Inc. (ADR)(NASDAQ:BIDU) is up handsomely today, mostly thanks to an upgrade from Morgan Stanley. read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.